HC Wainwright Estimates LifeMD’s Q2 Earnings (NASDAQ:LFMD)

LifeMD, Inc. (NASDAQ:LFMD) – Equities researchers at HC Wainwright lowered their Q2 2026 earnings estimates for shares of LifeMD in a report issued on Tuesday, May 26th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.24) per share for the quarter, down from their prior forecast of $0.06. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for LifeMD’s current full-year earnings is $0.04 per share. HC Wainwright also issued estimates for LifeMD’s Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at ($0.47) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.12) EPS, Q4 2027 earnings at $0.15 EPS and FY2027 earnings at ($0.01) EPS.

LFMD has been the topic of a number of other reports. Wall Street Zen lowered shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. UBS Group reiterated a “buy” rating on shares of LifeMD in a report on Wednesday. Weiss Ratings upgraded shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a report on Thursday, May 7th. Loop Capital set a $10.00 price target on shares of LifeMD in a report on Thursday, March 12th. Finally, BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of LifeMD in a report on Monday, May 4th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.14.

LifeMD Stock Up 0.4%

LifeMD stock opened at $4.59 on Friday. The firm has a market cap of $221.97 million, a PE ratio of 91.82 and a beta of 2.03. LifeMD has a 52-week low of $2.56 and a 52-week high of $15.84. The company’s 50 day moving average is $4.16 and its two-hundred day moving average is $3.77.

LifeMD (NASDAQ:LFMD) last released its earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). The business had revenue of $50.16 million for the quarter, compared to analyst estimates of $48.84 million. LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of LifeMD in the 4th quarter valued at $36,000. Magnus Financial Group LLC purchased a new position in shares of LifeMD in the 4th quarter valued at $41,000. R Squared Ltd purchased a new position in shares of LifeMD in the 1st quarter valued at $41,000. Jain Global LLC purchased a new position in shares of LifeMD in the 4th quarter valued at $45,000. Finally, Quarry LP purchased a new position in shares of LifeMD in the 3rd quarter valued at $52,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD News Roundup

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on LifeMD and kept its $10 price objective, signaling continued upside potential versus the current share price.
• Positive Sentiment: The firm’s updated models still point to improved profitability later on, including a forecast of $0.15 EPS for Q4 2027, which suggests confidence in LifeMD’s longer-term earnings power.
• Neutral Sentiment: HC Wainwright’s FY2027 estimate of ($0.01) EPS is roughly near breakeven, implying a transition period rather than a clear catalyst either way.
• Negative Sentiment: HC Wainwright lowered FY2026 EPS to ($0.47) from ($0.33), a meaningful downgrade that may pressure shares by reinforcing concerns about near-term losses.
• Negative Sentiment: The analyst also reduced Q2 2026, Q3 2026, and Q4 2026 earnings estimates, indicating softer expectations for LifeMD’s upcoming results.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.